Harmonizing Definitions in Liquid Biopsy: A Terminology Framework by the International Society of Liquid Biopsy

The rapid expansion of liquid biopsy (LB) throughout the cancer care continuum is evidenced by the striking increase in annual publications, rising from approximately 100 per year in the early 2000s to more than 2,200 in recent years.This exponential growth reflects the accelerating impact of LB across precision medicine.However, the field's evolution has been accompanied by inconsistent use of key terminology, creating barriers to clear communication, comparability of results, and appropriate clinical translation.To address this challenge, the International Society of Liquid Biopsy (ISLB) presents a comprehensive and harmonized terminology framework, an essential and timely effort to support the coherent advancement of the LB discipline.ISLB defines LB as the analysis of cells, nucleic acids, proteins, metabolites, and extracellular vesicles used to interrogate pathological or specific physiological conditions, obtained from bodily fluids, primarily through minimally invasive methods.Here we discuss relevant biospecimens, emphasizing their distinct sources and molecular characteristics.A central component of the manuscript is a rigorous clarification of analyte-specific terminology.This includes circulating free DNA and RNA (cfDNA, cfRNA), circulating tumor DNA and RNA (ctDNA, ctRNA), tumor fraction (TF), variant allele frequency (VAF), circulating tumor cells (CTCs), disseminated tumor cells (DTCs), circulating tumor microemboli (CTMs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), soluble proteins, and metabolomic signatures.The manuscript also outlines the analytical methodologies, that enable sensitive detection of low-abundance tumorderived signals.Clinical applications of LB in Oncology are defined across the disease continuum, including early cancer detection, molecular residual disease (MoRD) assessment, predictive biomarker evaluation, and tumor monitoring.By establishing a cohesive vocabulary, ISLB provides a robust reference framework that will evolve with scientific progress and guide the integration of LB into precision medicine.

Authors

Institutions

Publication Details

Journal
The Journal of Liquid Biopsy
Published
2026-03-01
DOI
https://doi.org/10.1016/j.jlb.2026.100462
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Harmonizing Definitions in Liquid Biopsy: A Terminology Framework by the International Society of Liquid Biopsy

Luis E. Raez, María José Serrano, Clara Mayo de las Casas, Ola Khorshid et al.
The Journal of Liquid Biopsy
Cancer Genomics and Diagnostics
article

Harmonizing Definitions in Liquid Biopsy: A Terminology Framework by the International Society of Liquid Biopsy

Luis E. Raez, María José Serrano, Clara Mayo de las Casas, Ola Khorshid, Carolina Reduzzi, Eloísa Jantus-Lewintre, Umberto Malapelle, Yuksel Urum, Natasha B. Leighl, Christian Rolfo, Silvia Calabuig-Fariñas, Charu Aggarwal, David Gandara, Nicola Fusco
article en

Abstract

The rapid expansion of liquid biopsy (LB) throughout the cancer care continuum is evidenced by the striking increase in annual publications, rising from approximately 100 per year in the early 2000s to more than 2,200 in recent years.This exponential growth reflects the accelerating impact of LB across precision medicine.However, the field's evolution has been accompanied by inconsistent use of key terminology, creating barriers to clear communication, comparability of results, and appropriate clinical translation.To address this challenge, the International Society of Liquid Biopsy (ISLB) presents a comprehensive and harmonized terminology framework, an essential and timely effort to support the coherent advancement of the LB discipline.ISLB defines LB as the analysis of cells, nucleic acids, proteins, metabolites, and extracellular vesicles used to interrogate pathological or specific physiological conditions, obtained from bodily fluids, primarily through minimally invasive methods.Here we discuss relevant biospecimens, emphasizing their distinct sources and molecular characteristics.A central component of the manuscript is a rigorous clarification of analyte-specific terminology.This includes circulating free DNA and RNA (cfDNA, cfRNA), circulating tumor DNA and RNA (ctDNA, ctRNA), tumor fraction (TF), variant allele frequency (VAF), circulating tumor cells (CTCs), disseminated tumor cells (DTCs), circulating tumor microemboli (CTMs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), soluble proteins, and metabolomic signatures.The manuscript also outlines the analytical methodologies, that enable sensitive detection of low-abundance tumorderived signals.Clinical applications of LB in Oncology are defined across the disease continuum, including early cancer detection, molecular residual disease (MoRD) assessment, predictive biomarker evaluation, and tumor monitoring.By establishing a cohesive vocabulary, ISLB provides a robust reference framework that will evolve with scientific progress and guide the integration of LB into precision medicine.

The Journal of Liquid Biopsy
Cairo University (EG), Ankara University (TR), Universitat de València (ES), University of Milan (IT), Cornell University (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Instituto de Salud Carlos III (ES), Princess Margaret Cancer Centre (CA), Instituto Oncológico Dr. Rosell (ES), Memorial Healthcare System (US), USP Institut Universitari Dexeus (ES), Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Centro de Investigacion Principe Felipe (ES), Universitat Politècnica de València (ES), European Institute of Oncology (IT), University of Naples Federico II (IT), University of Pennsylvania (US), Florida Memorial University (US), University of California, Davis (US)
Partnerships for the goals
Openalex Percentile: Top 9%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.